[
  {
    "ts": null,
    "headline": "Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note",
    "summary": "Pfizer (PFE) closed at $24.5 in the latest trading session, marking a -1.09% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=c328ee4880b0222250fd628b491d652bfce6daf9ea0c0af55b666fa2e3311891",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761687904,
      "headline": "Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note",
      "id": 137243712,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) closed at $24.5 in the latest trading session, marking a -1.09% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=c328ee4880b0222250fd628b491d652bfce6daf9ea0c0af55b666fa2e3311891"
    }
  },
  {
    "ts": null,
    "headline": "Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors",
    "summary": "Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Ted W. Love, M.D., has been appointed to the Company's Board of Directors, effective December 1, 2025. Dr. Love brings more than 30 years of expertise in drug development and global commercialization to the Company's Board.",
    "url": "https://finnhub.io/api/news?id=169afe0bb6e8cdacc0bf79d46361e5601a968c6e12101add74735c53e08755b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761681900,
      "headline": "Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors",
      "id": 137243713,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Ted W. Love, M.D., has been appointed to the Company's Board of Directors, effective December 1, 2025. Dr. Love brings more than 30 years of expertise in drug development and global commercialization to the Company's Board.",
      "url": "https://finnhub.io/api/news?id=169afe0bb6e8cdacc0bf79d46361e5601a968c6e12101add74735c53e08755b8"
    }
  },
  {
    "ts": null,
    "headline": "5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade",
    "summary": "There’s no better way to generate passive income than dividend stocks. If a stock has a dividend yield higher than the common benchmark, such as the S&P 500, it could be a worthwhile investment. The dividend yield of the S&P 500 averages 1.2%, nearing its record low. Fortunately, there are several dividend stocks with a ... 5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade",
    "url": "https://finnhub.io/api/news?id=a8c10cb6793dfdf9b716d9feb81fe0904c8dccdd675eee04e61361f58c2ce1c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761678917,
      "headline": "5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade",
      "id": 137243714,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "There’s no better way to generate passive income than dividend stocks. If a stock has a dividend yield higher than the common benchmark, such as the S&P 500, it could be a worthwhile investment. The dividend yield of the S&P 500 averages 1.2%, nearing its record low. Fortunately, there are several dividend stocks with a ... 5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade",
      "url": "https://finnhub.io/api/news?id=a8c10cb6793dfdf9b716d9feb81fe0904c8dccdd675eee04e61361f58c2ce1c1"
    }
  },
  {
    "ts": null,
    "headline": "3 Stocks Under $30: Where to Put $1,000 to Work Today",
    "summary": "The democratization of investing started with discount brokers slashing commissions and advanced through no-transaction-fee trading on apps like Robinhood (NASDAQ:HOOD) and Fidelity. Now, it no longer takes a lot of money to make money on Wall Street, as investors can buy fractional shares with as little as $5 or $10. That opens doors for everyday ... 3 Stocks Under $30: Where to Put $1,000 to Work Today",
    "url": "https://finnhub.io/api/news?id=e17a41c5d75533cae12cbe1fc362f95df304b7465750608df68a13a3f669ddfe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761672328,
      "headline": "3 Stocks Under $30: Where to Put $1,000 to Work Today",
      "id": 137243715,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The democratization of investing started with discount brokers slashing commissions and advanced through no-transaction-fee trading on apps like Robinhood (NASDAQ:HOOD) and Fidelity. Now, it no longer takes a lot of money to make money on Wall Street, as investors can buy fractional shares with as little as $5 or $10. That opens doors for everyday ... 3 Stocks Under $30: Where to Put $1,000 to Work Today",
      "url": "https://finnhub.io/api/news?id=e17a41c5d75533cae12cbe1fc362f95df304b7465750608df68a13a3f669ddfe"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors despite losses on the day",
    "summary": "Pfizer Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=96fa38efd619d82da6f1f13095908e40c7a08708b29b18552f07a27f150c6f57",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761669420,
      "headline": "Pfizer Inc. stock outperforms competitors despite losses on the day",
      "id": 137252319,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=96fa38efd619d82da6f1f13095908e40c7a08708b29b18552f07a27f150c6f57"
    }
  },
  {
    "ts": null,
    "headline": "Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know",
    "summary": "MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.",
    "url": "https://finnhub.io/api/news?id=c59977d629be90dfa5414d1c82c1ee5dab700969b25f3f1cb55902e3ea7c0ed7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761669420,
      "headline": "Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know",
      "id": 137243529,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.",
      "url": "https://finnhub.io/api/news?id=c59977d629be90dfa5414d1c82c1ee5dab700969b25f3f1cb55902e3ea7c0ed7"
    }
  },
  {
    "ts": null,
    "headline": "3 Cancer-Focused Stocks Showing Strong Pipeline Progress",
    "summary": "Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.",
    "url": "https://finnhub.io/api/news?id=8563a14a3ef258858ea8c55d378e17f5312e20744e165be336f0e7dd071263c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761665700,
      "headline": "3 Cancer-Focused Stocks Showing Strong Pipeline Progress",
      "id": 137243278,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.",
      "url": "https://finnhub.io/api/news?id=8563a14a3ef258858ea8c55d378e17f5312e20744e165be336f0e7dd071263c1"
    }
  },
  {
    "ts": null,
    "headline": "Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?",
    "summary": "CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.",
    "url": "https://finnhub.io/api/news?id=8bd25d297520a1529b3ff1abdc15ff9d55a73ffa36be6a38a52139468ea0e6be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761662400,
      "headline": "Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?",
      "id": 137243718,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.",
      "url": "https://finnhub.io/api/news?id=8bd25d297520a1529b3ff1abdc15ff9d55a73ffa36be6a38a52139468ea0e6be"
    }
  },
  {
    "ts": null,
    "headline": "The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products",
    "summary": "Organon stock plunged after CEO's exit and audit probe. Discover if its low valuation, global portfolio, and earnings catalysts make it a buy now.",
    "url": "https://finnhub.io/api/news?id=cf489c10d6d73c61b67e2899cb8f6f0e7b09d7f579ed86a83537732afa102807",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761660375,
      "headline": "The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products",
      "id": 137240047,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1940034961/image_1940034961.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Organon stock plunged after CEO's exit and audit probe. Discover if its low valuation, global portfolio, and earnings catalysts make it a buy now.",
      "url": "https://finnhub.io/api/news?id=cf489c10d6d73c61b67e2899cb8f6f0e7b09d7f579ed86a83537732afa102807"
    }
  },
  {
    "ts": null,
    "headline": "Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline",
    "summary": "Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=33b06ffa8d302a58a4bdbb948e91d1bf9c3f365247638a78be4703b93dd5fef1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761660039,
      "headline": "Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline",
      "id": 137243400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=33b06ffa8d302a58a4bdbb948e91d1bf9c3f365247638a78be4703b93dd5fef1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Whistleblower's Story Unveiled: Becky McClain's \"Exposed\" Memoir Hits Shelves October 28",
    "summary": "In a gripping new release from Skyhorse Publishing, molecular biologist and whistleblower Becky McClain lays bare her harrowing journey in \"Exposed,\" a book that promises to shake the foundations of corporate accountability and government oversight within the biotech industry. Set for wide release on October 28, \"Exposed\" chronicles McClain's years-long battle against pharmaceutical giant Pfizer, following her allegations of unsafe laboratory practices and the retaliation she says she endured fo",
    "url": "https://finnhub.io/api/news?id=b90bf9c0244f2f0625dbf06aa39831f2cdc401dc53d5933d10ed8ce1cc2d6dec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761655140,
      "headline": "Pfizer Whistleblower's Story Unveiled: Becky McClain's \"Exposed\" Memoir Hits Shelves October 28",
      "id": 137237987,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In a gripping new release from Skyhorse Publishing, molecular biologist and whistleblower Becky McClain lays bare her harrowing journey in \"Exposed,\" a book that promises to shake the foundations of corporate accountability and government oversight within the biotech industry. Set for wide release on October 28, \"Exposed\" chronicles McClain's years-long battle against pharmaceutical giant Pfizer, following her allegations of unsafe laboratory practices and the retaliation she says she endured fo",
      "url": "https://finnhub.io/api/news?id=b90bf9c0244f2f0625dbf06aa39831f2cdc401dc53d5933d10ed8ce1cc2d6dec"
    }
  },
  {
    "ts": null,
    "headline": "With 67% ownership, Pfizer Inc. (NYSE:PFE) boasts of strong institutional backing",
    "summary": "Key Insights Institutions' substantial holdings in Pfizer implies that they have significant influence over the...",
    "url": "https://finnhub.io/api/news?id=0aed342a1debe04c3ce1c6469644811ab1a46026fd36bfb0afba3103967d96f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761652909,
      "headline": "With 67% ownership, Pfizer Inc. (NYSE:PFE) boasts of strong institutional backing",
      "id": 137237988,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Key Insights Institutions' substantial holdings in Pfizer implies that they have significant influence over the...",
      "url": "https://finnhub.io/api/news?id=0aed342a1debe04c3ce1c6469644811ab1a46026fd36bfb0afba3103967d96f0"
    }
  },
  {
    "ts": null,
    "headline": "United States Adult Vaccine Market Research and Company Analysis Report 2025-2033 Featuring GlaxoSmithKline, AstraZeneca, Sanofi Pasteur, Pfizer, and CSL Limited",
    "summary": "The United States Adult Vaccine Market is projected to soar to US$ 11.10 billion by 2033, up from US$ 6.55 billion in 2024, with a steady CAGR of 6.03% between 2025 and 2033. This growth is propelled by increased awareness, advancements in biotechnology, and robust government support. The market is driven by the demand for vaccines tackling influenza, shingles, and hepatitis, with states like California, Texas, New York, and Florida leading adoption due to strong healthcare infrastructures. Desp",
    "url": "https://finnhub.io/api/news?id=a52f9c17f3ce83be5fe44232d2aaf4b08bf3667c25c5c9d32a66a5d636e39d38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761648660,
      "headline": "United States Adult Vaccine Market Research and Company Analysis Report 2025-2033 Featuring GlaxoSmithKline, AstraZeneca, Sanofi Pasteur, Pfizer, and CSL Limited",
      "id": 137237989,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The United States Adult Vaccine Market is projected to soar to US$ 11.10 billion by 2033, up from US$ 6.55 billion in 2024, with a steady CAGR of 6.03% between 2025 and 2033. This growth is propelled by increased awareness, advancements in biotechnology, and robust government support. The market is driven by the demand for vaccines tackling influenza, shingles, and hepatitis, with states like California, Texas, New York, and Florida leading adoption due to strong healthcare infrastructures. Desp",
      "url": "https://finnhub.io/api/news?id=a52f9c17f3ce83be5fe44232d2aaf4b08bf3667c25c5c9d32a66a5d636e39d38"
    }
  },
  {
    "ts": null,
    "headline": "Top Pharmaceutical Companies Shaping The Future Of Healthcare",
    "summary": "Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in GLP-1s, oncology, and pipeline strength.",
    "url": "https://finnhub.io/api/news?id=d8552c40676d75188ca76593380e6229d38d1c1093cfb419146ba101bc053f8c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761648180,
      "headline": "Top Pharmaceutical Companies Shaping The Future Of Healthcare",
      "id": 137238505,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1349026574/image_1349026574.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in GLP-1s, oncology, and pipeline strength.",
      "url": "https://finnhub.io/api/news?id=d8552c40676d75188ca76593380e6229d38d1c1093cfb419146ba101bc053f8c"
    }
  }
]